Bioyong Clin-ICP-QMS-I Clinical Inductively Coupled Plasma Quadrupole Mass Spectrometer

Overview

The Bioyong Clin-ICP-QMS-I is a CE-marked, NMPA-registered clinical-grade inductively coupled plasma quadrupole mass spectrometer engineered specifically for quantitative trace elemental and isotopic analysis in human biological matrices. It operates on the fundamental principle of ionization via high-temperature argon plasma (≥7,000 K), followed by mass separation using a radiofrequency-driven quadrupole mass filter and detection via secondary electron multiplier. Unlike research-grade ICP-MS systems optimized for ultra-trace environmental or geological applications, the Clin-ICP-QMS-I integrates hardware and software architecture aligned with clinical laboratory workflow requirements—including regulated sample introduction (autosampler with integrated dilution and internal standard addition), real-time interference monitoring, and audit-ready data handling. Its design reflects compliance with ISO 15189:2022 pre-analytical and analytical performance validation frameworks and supports method transfer from established CDC-recommended protocols for blood and urine elemental profiling.

Key Features

• Clinical-validated configuration: Pre-installed, NMPA-cleared assay methods for 28 essential/toxic elements (e.g., Fe, Zn, Cu, Se, As, Cd, Pb, U) in serum, plasma, whole blood, and urine—aligned with CLIA-equivalent precision criteria.
• Dual-mode collision/reaction cell: Equipped with helium and hydrogen gas modes to suppress oxide-based (e.g., ⁴⁰Ar¹⁶O⁺) and polyatomic interferences (e.g., ⁴⁰Ar³⁵Cl⁺), enabling accurate quantification of key isotopes such as ⁵⁶Fe, ⁷⁵As, and ²⁰⁸Pb in complex biological digests.
• Integrated sample preparation interface: Direct coupling with certified clinical digestion modules (microwave-assisted acid digestion per ASTM D5688-22) and online internal standardization (Sc, Rh, Re, Ir, Bi) to correct for matrix-induced signal drift and nebulization efficiency variation.
• Regulatory-ready data architecture: Built-in 21 CFR Part 11-compliant user access control, electronic signature logging, and immutable audit trails for all acquisition, processing, and reporting events.
• High-throughput clinical workflow: Supports batch processing of up to 96 samples per run with automated calibration curve generation, QC failure flagging, and LIS/HIS-compatible HL7 v2.5 output.

Sample Compatibility & Compliance

The Clin-ICP-QMS-I is validated for direct analysis of diluted (1:10–1:100) and microwave-digested clinical specimens—including EDTA-anticoagulated whole blood, serum, urine, and hair homogenates—without requiring offline separation or pre-concentration. All method validations adhere to CLSI EP28-A3c guidelines for reference interval establishment and CLSI EP17-A2 for limit-of-detection/quantitation assessment. The system meets the analytical performance specifications outlined in WS/T 107.2–2016 (Determination of iodine in urine by ICP-MS) and supports implementation of CDC’s recommended protocols for urinary cadmium and blood lead testing (CDC Laboratory Guidelines, 2021 Edition). Instrument qualification follows IQ/OQ/PQ protocols compliant with ISO/IEC 17025:2017 and GCP/GLP documentation standards.

Software & Data Management

The instrument is controlled by Bioyong ClinSuite™ v4.2—a FDA 21 CFR Part 11-compliant software platform featuring role-based access control, configurable electronic worksheets, and automated report generation in PDF/A-2 format. Raw data files (.raw) are stored in vendor-neutral mzML 1.1 format, ensuring long-term archival integrity and third-party compatibility (e.g., Skyline, OpenMS). All calibration curves include weighted linear regression (1/x²), residual diagnostics, and outlier detection per ICH Q2(R2) principles. Audit logs capture timestamped records of method edits, result reprocessing, and user authentication events—fully traceable during regulatory inspections.

Applications

• Quantitative assessment of nutritional status (e.g., Zn, Cu, Se deficiency in chronic kidney disease patients)
• Toxic metal screening (e.g., Pb, Cd, Hg exposure monitoring in occupational health programs)
• Therapeutic drug monitoring involving metallodrugs (e.g., Pt-based chemotherapeutics, Li in bipolar disorder management)
• Isotopic ratio analysis for metabolic tracing studies (e.g., ⁶⁷Zn/⁶⁴Zn in zinc absorption trials)
• Reference method development for national clinical reference laboratories seeking ISO 15197:2015-aligned traceability

FAQ

Is the Clin-ICP-QMS-I compliant with FDA or EU IVDR requirements?
Yes—the system meets essential requirements of Regulation (EU) 2017/746 (IVDR) Annex I for Class C in vitro diagnostic devices and supports submission-ready technical documentation packages for both FDA 510(k) and EU Notified Body review.
Can it be integrated into existing hospital LIS systems?
Yes—HL7 v2.5 and ASTM E1384-compliant messaging interfaces are included, with optional FHIR R4 adapters available upon request.
What sample volume is required per analysis?
Typical requirement is 100–200 µL of undiluted serum or urine; for whole blood, 50 µL post-dilution (1:20) is sufficient.
Does the system support isotope dilution mass spectrometry (IDMS)?
Yes—pre-configured IDMS workflows for Fe, Zn, and Mg are included, with certified isotopically enriched standards traceable to NIST SRM 3109a and IRMM-3702.
What maintenance schedule is recommended for clinical operation?
Daily autotune and torch alignment, weekly cone cleaning, and quarterly quadrupole mass calibration using certified tuning solution (Bioyong QC-MS-01)—all documented within the built-in preventive maintenance log.